Developmental Research Program

发展研究计划

• 批准号: 10286763
• 负责人: George Ioannou
• 金额: $ 6.52万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-06 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10286763
• 关键词: Alaska Native; American Indians; Area; Basic Science; Biometry; Cancer Center Planning Grant; Cancer Research Project; Cessation of life; Cherokee Indian; Clinical; Clinical Sciences; Collaborations; Colorectal Cancer; Development; Early Diagnosis; Epidemiology; Etiology; Face; Faculty; Feedback; Foundations; Fred Hutchinson Cancer Research Center; Functional disorder; Funding; Goals; Government; Grant; Health Services; Incidence; Infrastructure; Institution; Investments; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of prostate; Manuscripts; Medical center; Monitor; Morbidity - disease rate; Native-Born; Outcome; Patients; Persons; Phase; Population; Population Study; Prevention; Primary carcinoma of the liver cells; Prognosis; Program Research Project Grants; Quality of life; Reporting; Research; Research Personnel; Research Project Grants; Research Proposals; Resources; Scientist; Site; Source; Structure; Talents; Texas; Therapeutic; Time; Translational Research; Travel; Universities; Washington; Woman; Work; anticancer research; base; cancer health disparity; cancer therapy; design; disparity elimination; ethnic diversity; experience; feasibility testing; gender diversity; improved; innovation; interest; malignant breast neoplasm; medical schools; meetings; member; men; mortality; multidisciplinary; novel; programs; racial and ethnic; research study; survivorship; translational approach; tribal health

ABSTRACT: DEVELOPMENTAL AND RESEARCH PROGRAM CORE The Developmental Research Program (DRP) of the Liver Cancer in American Indians/Alaska Natives (AI/AN) Disparities (Li-CAD) P20 Program will support early-phase projects that have the potential to open new areas of translational liver cancer research and ultimately, contribute to reducing morbidity and mortality and improving quality-of-life for patients with hepatocellular carcinoma (HCC). Projects funded under the DRP are intended to rapidly advance a new idea or concept that has the potential to substantially impact our understanding of liver cancer to eliminate disparities and improve surveillance, early detection, and treatment of HCC in AI/AN persons and thereby reduce or eliminate HCC-related mortality. The infrastructure of the DRP will establish mechanisms to quickly respond to translational research opportunities within the Li-CAD P20 Program institutions that require support to advance hypotheses or confirm feasibility in order to justify larger resource investments. Developmental projects will include research in basic science, clinical science, and population-based studies, and will build collaborations between Li-CAD sites and other institutions with P20 Programs and SPOREs in liver cancer and disparities research. Developmental projects may encompass a wide range of liver cancer research and treatment areas, including basic science, etiology and prevention (primary and secondary), early detection, prognosis, therapeutics, and survivorship. Collectively, the DRP is structured to strengthen collaborations between Li-CAD sites and initiate interactions with other institutions with P20 Programs and SPOREs in liver cancer. DRP proposals will be supported based on their potential to mature an original idea or concept into a translational research project that will successfully attain independent funding, either within a subsequent P50 or from other government or foundation sources. In addition, the DRP is designed to attract senior investigators with diverse scientific expertise and junior investigators new to translational liver cancer research. The Specific Aims for the Developmental Research Program are to: 1. Stimulate the development of innovative, impactful, early-phase research studies that include multidisciplinary interactions with basic, clinical, and population scientists across the Li-CAD institutions; 2. Provide funding (1-2 years) and infrastructure (e.g., biospecimens, biostatistical support) to rapidly test the feasibility of original investigator-initiated projects in all areas of HCC research; 3. Prioritize funding to rapidly exploit new opportunities or support specific areas of strategic importance for advancing the translational research goals of the Li-CAD P20 Program; and 4. Monitor (and facilitate) the progress of each DRP project and consider their advancement to a full P50 SPORE project.

摘要：发展和研究计划核心 美国印第安人/阿拉斯加原住民（AI/AN）肝癌的发展研究计划（DRP） 差异（Li-CAD）P20计划将支持有潜力开辟新领域的早期项目。 转化肝癌研究，并最终有助于降低发病率和死亡率， 肝细胞癌（HCC）患者的生活质量。由“减贫策略”资助的项目， 迅速提出一个新的想法或概念，有可能对我们对肝脏的理解产生重大影响。 在AI/AN患者中消除差异并改善HCC的监测、早期发现和治疗 从而降低或消除HCC相关死亡率。DRP的基础设施将建立机制， 快速响应Li-CAD P20计划机构内的转化研究机会， 支持提出假设或确认可行性，以证明更大的资源投资是合理的。 发展项目将包括基础科学、临床科学和基于人口的研究， 并将在Li-CAD研究中心与其他具有肝脏P20计划和SPORE的机构之间建立合作关系 癌症和差异研究。 发展项目可能涵盖广泛的肝癌研究和治疗领域，包括 基础科学，病因学和预防（初级和二级），早期发现，预后，治疗学， 生存。总体而言，DRP旨在加强Li-CAD研究中心之间的合作，并启动 与其他具有P20项目和肝癌SPORE的机构进行互动。DRP提案将 支持基于他们的潜力成熟的原始想法或概念转化为研究项目， 将成功获得独立的资金，无论是在随后的P50或从其他政府或 基金会来源。此外，DRP旨在吸引具有不同科学知识的高级研究人员， 专业知识和初级研究人员新的转化肝癌研究。 发展研究计划的具体目标是： 1.促进创新，有影响力的早期研究的发展，包括 与Li-CAD机构的基础、临床和人口科学家进行多学科互动; 2.提供资金（1-2年）和基础设施（例如，生物样本，生物统计支持）进行快速检测 在HCC研究的所有领域中，最初的研究者发起的项目的可行性; 3.优先提供资金，以迅速利用新的机会或支持具有战略重要性的具体领域， 推进Li-CAD P20计划的转化研究目标; 4.监控（并促进）每个DRP项目的进展，并考虑将其推进到完整的P50 SPORE项目。